ABCL vs ZBIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ABCL Captures Institutional Edge (3โ1 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to AbCellera Biologics Inc. Common Shares (ABCL) driven by superior Valuation, Growth & Margin, Momentum & Technical while ZBIO counters with relative strength in Options & Structure. Fundamentally, ABCL trades at 27.6x Forward P/E with -1550.0% operating margin (-76.3% YoY revenue) versus ZBIO at N/M Forward P/E and -2747.5% operating margin (-100.0% YoY). In options structure, ABCL sits in CONSOLIDATION (29th %ile IV; Dealer Gamma Walls on Pro) against ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ABCL Revenue | ZBIO Revenue | ABCL Op. Margin | ZBIO Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $10M | N/A | -35.5% | N/A | ABCL |
| FY2020 | $230M | N/A | 66.9% | N/A | ABCL |
| FY2021 | $380M | N/A | 54.5% | N/A | ABCL |
| FY2022 | $490M | N/A | 44.6% | N/A | ABCL |
| FY2023 | $40M | $50M | -623.8% | -74.3% | ZBIO |
| FY2024 | $30M | $10M | -1091.7% | -3277.8% | ABCL |
| FY2025 | $80M | $10M | -289.0% | -3830.6% | ABCL |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ABCL | ZBIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.8B | $1.9B | Larger Scale | ABCL |
| Trailing P/E Ratio Valuation | 27.6x | N/M | Lower Multiple | ABCL |
| Forward P/E Ratio Valuation | 27.6x | N/M | Lower Multiple | ABCL |
| Revenue Growth (YoY) Growth | -76.3% | -100.0% | Higher Growth | ABCL |
| Operating Margin (TTM) Profitability | -1550.0% | -2747.5% | Higher Margin | ABCL |
| Net Profit Margin Profitability | -248.8% | 0.0% | Higher Margin | ZBIO |
| Return on Equity (ROE) Capital Efficiency | -17.3% | -265.1% | Higher ROE | ABCL |
| 52-Week Range Position Momentum | 68% ($3โ$15) | 46% ($14โ$45) | Stronger Trend | ABCL |
| Beta / 30D Volatility Risk Regime | 2.30ฮฒ ยท 87% Vol | 1.16ฮฒ ยท 59% Vol | Lower Realized Risk | ZBIO |
| Unified Institutional Score Composite Signal | 63.3 / 100 (BUY) | 49.4 / 100 (HOLD) | Higher Composite | ABCL |